In 1975, the Durie-Salmon Staging System was developed, bringing together the major clinical parameters in correlation with measured myeloma cell mass (the total number of myeloma cells in the body). The Durie-Salmon Staging System demonstrates the correlation between the amount of myeloma and the damage it has caused, such as bone disease or anemia. The following table details the stages and criteria for measuring the presence and staging of multiple myeloma.
| Stage | Criteria | Measured Myeloma Cell Mass (myeloma cells in billions/m2)* |
| Stage 1
(low cell mass) |
All of the following:
|
600 billion* |
| Stage II
(intermediate cell mass) |
Fitting neither Stage I nor Stage III |
600 to 1,200 billion* |
| Stage III
(high cell mass) |
One or more of the following:
|
>1,200 billion* |
| Subclassification (either A or B) |
Stage 1A (low cell mass with normal renal function); Stage IIB (high cell mass with abnormal renal function) |
What's Next?
Learn more about the International Staging System (ISS) and the Revised International Staging System (R-ISS).
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.
Last Medical Content Review: July 20, 2021